HRP20160171T1 - Liksisenatid za uporabu u lijeäśenju stenoze i/ili opstrukcije u sustavu kanala gušteraäśe - Google Patents
Liksisenatid za uporabu u lijeäśenju stenoze i/ili opstrukcije u sustavu kanala gušteraäśe Download PDFInfo
- Publication number
- HRP20160171T1 HRP20160171T1 HRP20160171TT HRP20160171T HRP20160171T1 HR P20160171 T1 HRP20160171 T1 HR P20160171T1 HR P20160171T T HRP20160171T T HR P20160171TT HR P20160171 T HRP20160171 T HR P20160171T HR P20160171 T1 HRP20160171 T1 HR P20160171T1
- Authority
- HR
- Croatia
- Prior art keywords
- treatment
- obstruction
- pancreatic duct
- use according
- pharmaceutical preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (11)
1. Farmaceutski pripravak za uporabu za liječenje bolesti ili stanja, naznačen time da je navedena bolest ili stanje povezana sa stenozom ili/i opstrukcijom smještenom u sustavu kanala gušterače, ili/i u okolnom tkivu gušterače, te navedeni pripravak sadrži liksisenatid ili/i njegovu farmaceutski prihvatljivu sol i proizvoljno farmaceutski prihvatljiv nosač, sredstvo za otapanje ili/i pomoćnu tvar.
2. Farmaceutski pripravak za uporabu prema zahtjevu 1, naznačen time da se stenoza ili/i opstrukcija nalazi u glavnom kanalu gušterače, u zajedničkom žučovodu i glavnom pankreatičnom vodu, u Vaterovoj ampuli, u Oddijevom sfinkteru, u akcesornom pankreatičnom vodu, ili/i u manjoj bradavici dvanaestnika.
3. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1 do 2, naznačen time da je opstrukcija uzrokovana s konkrementom smještenim u sustavu kanala gušterače, ili/i s litijazom.
4. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1 do 2, naznačen time da navedena bolest ili stanje je rak.
5. Farmaceutski pripravak za uporabu prema zahtjevu 4, naznačen time da rak je rak glavnog kanala gušterače, u zajedničkom žučovodu i glavnom pankreatičnom vodu, u Vaterovoj ampuli, u Oddijevom sfinkteru, u akcesornom pankreatičnom vodu, ili/i u manjoj bradavici dvanaesnika.
6. Farmaceutski pripravak za uporabu prema zahtjevu 4 ili 5, naznačen time da rak obuhvaća tumor.
7. Farmaceutski pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da stenoza ili/i opstrukcija uzrokuje bol.
8. Farmaceutski pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da liječenje je palijativno liječenje.
9. Farmaceutski pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da liječenje je liječenje od barem jedan mjesec, barem dva mjeseca, barem tri mjeseca, barem četiri mjeseca, ili barem šest mjeseci.
10. Farmaceutski pripravak za uporabu kod palijativnog liječenje bola uzrokovanog sa stenozom ili/i opstrukcijom u sustavu kanala gušterače, naznačen time da navedeni pripravak sadrži liksisenatid ili/i njegovu farmaceutski prihvatljivu sol i proizvoljno farmaceutski prihvatljiv nosač, sredstvo za otapanje ili/i pomoćnu tvar.
11. Farmaceutski pripravak za uporabu kod liječenje bola uzrokovanog sa stenozom ili/i opstrukcijom u sustavukanala gušterače, naznačen time da navedeni pripravak sadrži liksisenatid ili/i njegovu farmaceutski prihvatljivu sol i proizvoljno farmaceutski prihvatljiv nosač, sredstvo za otapanje ili/i pomoćnu tvar.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11183867 | 2011-10-04 | ||
| PCT/EP2012/069485 WO2013050379A1 (en) | 2011-10-04 | 2012-10-02 | Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the pancreatic duct system |
| EP12766695.6A EP2763690B1 (en) | 2011-10-04 | 2012-10-02 | Lixisenatide for use in the treatment of stenosis or/and obstruction in the pancreatic duct system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160171T1 true HRP20160171T1 (hr) | 2016-03-11 |
Family
ID=46963761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160171TT HRP20160171T1 (hr) | 2011-10-04 | 2012-10-02 | Liksisenatid za uporabu u lijeäśenju stenoze i/ili opstrukcije u sustavu kanala gušteraäśe |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130096060A1 (hr) |
| EP (1) | EP2763690B1 (hr) |
| CY (1) | CY1117394T1 (hr) |
| DK (1) | DK2763690T3 (hr) |
| ES (1) | ES2562651T3 (hr) |
| HR (1) | HRP20160171T1 (hr) |
| HU (1) | HUE028568T2 (hr) |
| PL (1) | PL2763690T3 (hr) |
| PT (1) | PT2763690E (hr) |
| SI (1) | SI2763690T1 (hr) |
| WO (1) | WO2013050379A1 (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102256618A (zh) | 2008-10-17 | 2011-11-23 | 赛诺菲-安万特德国有限公司 | 胰岛素和glp-1激动剂的组合 |
| PL2451437T3 (pl) | 2009-07-06 | 2017-05-31 | Sanofi-Aventis Deutschland Gmbh | Wodne preparaty insuliny zawierające metioninę |
| NZ599847A (en) | 2009-11-13 | 2013-09-27 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| TR201809460T4 (tr) | 2009-11-13 | 2018-07-23 | Sanofi Aventis Deutschland | Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim. |
| WO2012028172A1 (en) | 2010-08-30 | 2012-03-08 | Sanofi-Aventis Deutschland Gmbh | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| AR087693A1 (es) | 2011-08-29 | 2014-04-09 | Sanofi Aventis Deutschland | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
| US9895423B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| CN105960249B (zh) | 2014-01-09 | 2021-03-16 | 赛诺菲 | 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂 |
| JP6723921B2 (ja) | 2014-01-09 | 2020-07-15 | サノフイＳａｎｏｆｉ | インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤 |
| PE20171622A1 (es) | 2014-12-12 | 2017-11-02 | Sanofi Aventis Deutschland | Formulacion de relacion fija de insulina glargina/lixisenatida |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| EP4313016A4 (en) * | 2021-03-29 | 2025-01-22 | Sanford Health | METHODS AND COMPOSITIONS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES |
| KR20250128904A (ko) * | 2024-02-20 | 2025-08-28 | 가천대학교 산학협력단 | Trpv1 활성 매개 질환 치료용 약학적 조성물 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2038597A1 (en) * | 1991-03-19 | 1992-09-20 | Jose P. Garzaran | A method and a pharmaceutical preparation for treating pain |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| WO1998005351A1 (en) | 1996-08-08 | 1998-02-12 | Amylin Pharmaceuticals, Inc. | Methods for regulating gastrointestinal motility |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| EP0996459B1 (en) | 1997-01-07 | 2005-09-21 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the reduction of food intake |
| CA2299425A1 (en) | 1997-08-08 | 1999-02-18 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
| WO1999025727A2 (en) | 1997-11-14 | 1999-05-27 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
| ATE383867T1 (de) | 1997-11-14 | 2008-02-15 | Amylin Pharmaceuticals Inc | Neuartige exendin agonisten |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| EP1525219B1 (en) | 2002-07-04 | 2009-05-27 | Zealand Pharma A/S | Glp-1 and methods for treating diabetes |
| AU2003268621B2 (en) | 2002-10-02 | 2009-01-15 | Zealand Pharma A/S | Stabilized exendin-4 compounds |
| JP2009507050A (ja) | 2005-09-08 | 2009-02-19 | ガストロテック・ファルマ・アクティーゼルスカブ | 胆道ジスキネジーおよび／または胆道痛／不快の治療のためのｇｌｐ−１分子の使用 |
-
2012
- 2012-10-02 PL PL12766695T patent/PL2763690T3/pl unknown
- 2012-10-02 SI SI201230454T patent/SI2763690T1/sl unknown
- 2012-10-02 WO PCT/EP2012/069485 patent/WO2013050379A1/en not_active Ceased
- 2012-10-02 DK DK12766695.6T patent/DK2763690T3/en active
- 2012-10-02 HR HRP20160171TT patent/HRP20160171T1/hr unknown
- 2012-10-02 HU HUE12766695A patent/HUE028568T2/en unknown
- 2012-10-02 US US13/633,563 patent/US20130096060A1/en not_active Abandoned
- 2012-10-02 PT PT127666956T patent/PT2763690E/pt unknown
- 2012-10-02 EP EP12766695.6A patent/EP2763690B1/en not_active Not-in-force
- 2012-10-02 ES ES12766695.6T patent/ES2562651T3/es active Active
-
2016
- 2016-02-24 CY CY20161100151T patent/CY1117394T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2562651T3 (es) | 2016-03-07 |
| PL2763690T3 (pl) | 2016-04-29 |
| SI2763690T1 (sl) | 2016-03-31 |
| EP2763690B1 (en) | 2015-11-25 |
| WO2013050379A1 (en) | 2013-04-11 |
| EP2763690A1 (en) | 2014-08-13 |
| CY1117394T1 (el) | 2017-04-26 |
| PT2763690E (pt) | 2016-03-23 |
| DK2763690T3 (en) | 2016-02-15 |
| US20130096060A1 (en) | 2013-04-18 |
| HUE028568T2 (en) | 2016-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160171T1 (hr) | Liksisenatid za uporabu u lijeäśenju stenoze i/ili opstrukcije u sustavu kanala gušteraäśe | |
| HRP20200434T1 (hr) | Stabilne vodene formulacije adalimumaba | |
| JP2010222367A5 (hr) | ||
| WO2012103038A9 (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
| MX2012011222A (es) | Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales. | |
| NO340679B1 (no) | Pyridazinonderivativer, farmasøytiske preparater omfattende slike og slike forbindelser og preparater for anvendelse i terapeutisk aktive substanser til behandling og forebygging av sykdommer | |
| PH12013500215B1 (en) | Corticosteroids for the treatment of joint pain | |
| PH12015502136A1 (en) | Compositions and methods for treating non-alcoholic steatohepatitis | |
| GEP20125628B (en) | Pharmaceutical compositions containing antagonist anti-cd40 antibody | |
| EP2056818A4 (en) | COMPOSITIONS AND METHODS FOR NEUROPROTECTION | |
| WO2007101224A3 (en) | Inhibitors of the unfolded protein response and methods for their use | |
| CL2007000161A1 (es) | Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. | |
| EA202091999A3 (ru) | Применение ингибиторов dpp iv | |
| HK1214765A1 (zh) | 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途 | |
| EA201001865A1 (ru) | Противовоспалительные агенты | |
| CL2007002920A1 (es) | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. | |
| JP2013231087A5 (hr) | ||
| IL206080A0 (en) | Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases | |
| WO2010065950A3 (en) | Albumin binding peptide-mediated disease targeting | |
| CL2007003038A1 (es) | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. | |
| EA201370006A1 (ru) | Местная фармацевтическая композиция, содержащая флурбипрофен | |
| MA34670B1 (fr) | Inhibiteurs de l'apoptose et leurs utilisations | |
| WO2007143557A3 (en) | Compounds and methods for treating mammalian gastrointestinal parasitic infections | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use |